Nutex Health Inc

Nutex Health Inc(NUTX)财务数据

$197.610

-1.364 (-0.69%)收盘时

NUTX 收入构成

Nutex Health Inc (NUTX) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Hospital division, accounting for 95.9% of total sales, equivalent to $207.57M. Another important revenue stream is Population health management division. Understanding this composition is critical for investors evaluating how NUTX navigates market cycles within the Healthcare Facilities & Services industry.

NUTX 盈利能力与利润率

Evaluating the bottom line, Nutex Health Inc maintains a gross margin of 67.04%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 57.75%, while the net margin is 45.70%. These profitability ratios, combined with a Return on Equity (ROE) of 57.16%, provide a clear picture of how effectively NUTX converts its operational activities into shareholder value.

NUTX 同业对比

In the context of the broader market, NUTX competes directly with industry leaders such as USPH and GDRX. With a market capitalization of $1.27B, it holds a leading position in the sector. When comparing efficiency, NUTX's gross margin of 67.04% stands against USPH's 20.59% and GDRX's 78.41%. Such benchmarking helps identify whether Nutex Health Inc is trading at a premium or discount relative to its financial performance.

Nutex Health Inc 财务表现

Nutex Health has shown impressive financial performance with a gross margin of 67.04% in Q2 2026 and a year-over-year EPS growth of 2,785%.

Financials

FY2026Q2
YoY:
-13.62%
210.75M
Total Revenue
FY2026Q2
YoY:
+261.41%
121.72M
Operating Profit
FY2026Q2
YoY:
+496.61%
96.32M
Net Income after Tax
FY2026Q2
YoY:
-417.97%
9.38
EPS - Diluted
FY2026Q2
YoY:
+29.16%
31.66M
Free Cash Flow
FY2026Q2
YoY:
+25.61%
67.04
Gross Profit Margin - %
FY2026Q2
YoY:
+212.96%
32.11
FCF Margin - %
FY2026Q2
YoY:
+590.33%
45.70
Net Margin - %
FY2026Q2
YoY:
+77.12%
26.71
ROIC

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易